Key points are not available for this paper at this time.
From genome wide association studies there is increasing evidence of an aberrant immune response in IBD. 4 Susceptibility loci involve both the innate and adaptive immune response towards a diminished diversity of commensal microbiota. 5 Description of the numerous mechanisms contributing to this dysimmunity is beyond the scope of this article. Despite evidence of defective mucosal immunity, there is no proof of a systemic immune defect in patients with IBD in the absence of concomitant immunomodulator therapy.
Rahier et al. (Sat,) studied this question.